HIT Consultant May 16, 2024
Syed Hamza Sohail

What You Should Know:

Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, has secured $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing investors, including Health2047.

– The company has also been awarded a $2.3 million Phase II Small Business Innovation Research (SBIR) Grant through the National Institutes of Health (NIH).

Driving Precision Medicine in Obesity Treatment: Phenomix’s MyPhenome™ Test and Strategic Growth Initiatives

This infusion of capital will expedite the commercialization and uptake of the MyPhenome™ test within the obesity specialist market and broader industry. Equipping physicians with vital tools, the MyPhenome test facilitates the development of effective treatment strategies encompassing lifestyle...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Investments, Pharma / Biotech, Precision Medicine, Trends
Innovations in Preventive Care – Staying Ahead of Health Issues
Foresite Capital Closes $900M Fund Targeting Precision Medicine & Innovation
UK Biobank Pivoting to Platform-Only Model For Big Data Sharing
Precision medicine for sepsis in children within reach
GE Healthcare Unveils Solutions to Expand Access to Precision Medicine

Share This Article